Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ≥6months to ≤35 months-old healthy children (male or female) born at term after normal pregnancy~* Recording of medical history and physical examination reveal no abnormality~* The parent/legal guardian of the participating child must sign the written informed consent and agree to provide a blood sample taken from the child pre- and post-immunization~Exclusion criteria:~* Hypersensitivity to eggs, chicken proteins, polymyxin B, neomycin or any component of the vaccine~* Previous vaccination against influenza~* At time of enrollment, presentation of clinical symptoms of active infection and/or body temperature ≥38°C~* Confirmation or suspicion of immunosuppressed status (including cancer), or confirmation of immunodeficiency disease (congenital or acquired including HIV)~* Medical treatment (\>2 weeks) with immune suppressant or immune modulating drugs including systemic steroids during the last 3 months before immunization or at present, as follows: long-term oral prednisone or other equivalent steroid: ≥0.5mg/kg/day (note: administration of local or inhaled steroids before or during the study is allowed)~* Treatment with immunoglobulins or blood products during the last 3 months before immunization or such treatment scheduled during the study~* Participation in other clinical trials during the last 3 months before immunization or intention to participate during this study period~* At present or during the last 6 months before immunization: radiotherapy or treatment with cytotoxic drugs~* Other vaccination with a killed vaccine within 14 days before immunization or with an attenuated vaccine within 28 days before immunization (note: after subject inclusion vaccines of the immunization program for children are allowed upon the physician's discretion. However, immunization on the same day must be avoided)~* Family history of Guillain-Barré Syndrome~* Severe congenital deficiency or disease~* Antecedent of neurological disease or epileptic attack~* Severe cardiopulmonary disease with possibility to influence the study result~* Disturbance of coagulation or under anticoagulant treatment, likely to be contraindicated to i.m. injection~* Suspected non-compliance

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Inflexal 0.5 mL (Type: EXPERIMENTAL): None
- Inflexal 0.25 mL (Type: EXPERIMENTAL): None
- Agrippal 0.25 mL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).